AB Sciex Partners with Dalton on Developing Mass Spec-based Analyses of Antibody-Drug Conjugates | GenomeWeb

NEW YORK (GenomeWeb) – AB Sciex this week announced a collaboration with Dalton Pharma Services through which the mass spec vendor plans to develop methods for analysis of antibody-drug conjugates.

The company plans to build assays on its TripleTOF 5600+ and TripleTOF 6600 instruments for portions of the ADC development workflow including characterization of the conjugates' structures and analysis of their behavior and breakdown in vivo.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.